BIOCRYST PHARMACEUTICALS INC

Nasdaq:BCRX

Biological Products, (No Diagnostic Substances)·DURHAM, NC

CEO

Stonehouse Jon P

Financials

20 shown

Type	Period	Ended	Filed
10-K	FY 2025	12/31/25	2/26/26	→
10-Q	Q3 2025	9/30/25	11/4/25	→
10-Q	Q2 2025	6/30/25	8/5/25	→
10-Q	Q1 2025	3/31/25	5/6/25	→
10-K	FY 2024	12/31/24	2/25/25	→
10-Q	Q3 2024	9/30/24	11/5/24	→
↓

Earnings Releases (8-K)

25 shown

Filed	Period
2/26/26	Q1 FY2026	→
1/12/26	Q4 FY2026	→
11/3/25	Q4 FY2025	→
10/14/25	Q3 FY2025	→
8/4/25	Q3 FY2025	→
5/5/25	Q2 FY2025	→
↓

News (8-K)

55 shown

Filed	Type	Description
1/23/26	Exec Change	Departure or Appointment of Directors or Certain Officers	→
1/23/26	Acquisition	Entry into a Material Definitive Agreement	→
1/9/26	Reg FD	Regulation FD Disclosure	→
12/12/25	Other	Other Events	→
12/11/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
12/3/25	Other	Other Events	→
↓

Prospectuses & Registrations

40 shown

Filed	Form	Description
12/18/25	424B3	424B3	→
12/15/25	S-4/A	S-4/A	→
11/20/25	S-4	S-4	→
8/12/25	S-8	S-8	→
4/24/25	ARS	ARS	→
8/6/24	S-8	S-8	→
↓

Filing History(1002 filings)

TypeDateAccessionPeriodSize

Mar 3, 2026

0000882796-26-000013PRIMARY DOCUMENT

Feb 27, 2026

4.4 KB

Mar 3, 2026

0000882796-26-000011PRIMARY DOCUMENT

Feb 27, 2026

11.7 KB

Mar 3, 2026

0000882796-26-000009PRIMARY DOCUMENT

Feb 27, 2026

4.5 KB

Mar 3, 2026

0000882796-26-000007PRIMARY DOCUMENT

Feb 27, 2026

4.4 KB

Mar 3, 2026

0000882796-26-000005PRIMARY DOCUMENT

Feb 27, 2026

4.4 KB

144

Mar 2, 2026

0001959173-26-001679

—

4.3 KB

10-K

Feb 26, 2026

0001628280-26-01224010-K

Dec 31, 2025

14.5 MB

8-K

Feb 26, 2026

0001171843-26-001119FORM 8-K

Feb 26, 2026

425.3 KB

SCHEDULE 13G/A

Feb 12, 2026

0001193805-26-000127

—

16.4 KB

SCHEDULE 13G

Feb 9, 2026

0000093751-26-000024

—

7.8 KB

Jan 27, 2026

0000882796-26-000003PRIMARY DOCUMENT

Jan 23, 2026

9.2 KB

Jan 27, 2026

0001171843-26-000446

Jan 23, 2026

11.2 KB

8-K/A

Jan 23, 2026

0001171843-26-000405FORM 8-K/A

Oct 14, 2025

185.0 KB

8-K

Jan 23, 2026

0001140361-26-0022008-K

Jan 23, 2026

2.0 MB

8-K

Jan 12, 2026

0001171843-26-000213FORM 8-K

Jan 12, 2026

240.4 KB

Jan 9, 2026

0001171843-26-000173

Jan 1, 2026

20.1 KB

8-K

Jan 9, 2026

0001171843-26-000154FORM 8-K

Jan 9, 2026

181.1 KB

Dec 23, 2025

0000882796-25-000045PRIMARY DOCUMENT

Dec 19, 2025

6.0 KB

Dec 23, 2025

0000882796-25-000043PRIMARY DOCUMENT

Dec 19, 2025

6.3 KB

Dec 23, 2025

0000882796-25-000041PRIMARY DOCUMENT

Dec 19, 2025

15.1 KB

144

Dec 22, 2025

0001959173-25-007875

—

6.8 KB

Dec 19, 2025

0001171843-25-008039

Dec 18, 2025

15.9 KB

Dec 19, 2025

0001171843-25-008038

Dec 17, 2025

15.0 KB

Dec 19, 2025

0001171843-25-008037

Dec 17, 2025

14.9 KB

Dec 19, 2025

0000882796-25-000038PRIMARY DOCUMENT

Dec 17, 2025

6.7 KB

25 filings shown

Filed	Form	Description
4/24/25	DEFA14A	DEFA14A	→
4/24/25	DEF 14A	DEF 14A	→
4/25/24	DEFA14A	DEFA14A	→
4/25/24	DEF 14A	DEF 14A	→
4/27/23	DEFA14A	DEFA14A	→
4/27/23	DEF 14A	DEF 14A	→
↓

BIOCRYST PHARMACEUTICALS INC

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(1002 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
3/3/26	4	PRIMARY DOCUMENT	→
3/3/26	4	PRIMARY DOCUMENT	→
3/3/26	4	PRIMARY DOCUMENT	→
3/3/26	4	PRIMARY DOCUMENT	→
3/3/26	4	PRIMARY DOCUMENT	→
1/27/26	4	PRIMARY DOCUMENT	→
↓

Filed	Form	Description
3/2/26	144	144	→
2/12/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
2/9/26	SCHEDULE 13G	SCHEDULE 13G	→
12/22/25	144	144	→
12/18/25	EFFECT	EFFECT	→
12/15/25	144	144	→
↓